SCHEMBL8320902

SCHEMBL8320902

CN(C)c1ccc(-c2cnc3[nH]cc(-c4cccc(F)c4)c3c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.67
MAPK9 P45984 1/20 0.67
MAPK10 P53779 1/20 0.67
KIT P10721 6/20 0.65
NTRK1 P04629 1/20 0.61
AXL P30530 4/20 0.58
CDK8 P49336 1/20 0.58
TNIK Q9UKE5 1/20 0.58
MAP3K11 Q16584 1/20 0.57
CDK2 P24941 2/20 0.56
CDC7 O00311 1/20 0.56
ROCK2 O75116 1/20 0.56
MAP4K4 O95819 1/20 0.56
PIM1 P11309 1/20 0.56
PRKACA P17612 1/20 0.56
GSK3B P49841 1/20 0.56
HIPK2 Q9H2X6 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
IRAK4 Q9NWZ3 1/20 0.56
SGK1 O00141 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13620697 0.88 AXL (0.76) MAPK8MAPK9MAPK10KITNTRK1
SCHEMBL8320028 0.86 AXL (0.78) KITNTRK1AXLCDK8TNIK
SCHEMBL17319207 0.81 KIT (0.69) KITNTRK1AXLCDK8TNIK
SCHEMBL17319205 0.81 KIT (0.69) KITNTRK1AXLCDK8TNIK
SCHEMBL8298162 0.81 MAPK8 (0.72) MAPK8MAPK9MAPK10KITNTRK1
SCHEMBL8258597 0.81 MAPK8 (0.70) MAPK8MAPK9MAPK10KITNTRK1
SCHEMBL4406366 0.81 MAPK8 (1.00) MAPK8MAPK9MAPK10KITNTRK1
SCHEMBL4173910 0.79 NTRK1 (0.70) KITNTRK1AXLCDK8TNIK
SCHEMBL12763289 0.79 KIT (0.66) KITNTRK1AXLCDK8TNIK
SCHEMBL12763531 0.79 NTRK1 (0.84) MAPK8MAPK9MAPK10KITNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.